Cisplatin (Platinol ®)
BAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study
Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…
Read MoreSystemic treatment in patients with malignant pleural mesothelioma – real life experience
BMC Cancer 2022 April 20 [Link] Barbara Ziółkowska, Bożena Cybulska-Stopa, Dimitrios Papantoniou, Rafał Suwiński Abstract Background: Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural cavity linked to asbestos exposure. The combination of pemetrexed and platinum is a standard first-line therapy for malignant pleural mesothelioma. Despite some progress, almost all MPM patients…
Read MoreMinimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials
Lung Cancer 2022 March 29 [Link] Michael Koller, Jammbe Z Musoro, Krzysztof Tomaszewski, Corneel Coens, Madeleine T King, Mirjam A G Sprangers, Mogens Groenvold, Kim Cocks, Galina Velikova, Hans-Henning Flechtner, Andrew Bottomley Abstract Objectives: A minimally important difference (MID) is the smallest difference in quality of life (QoL) perceived as relevant by patients or clinicians.…
Read MoreAnetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
The Lancet Oncology 2022 April [Link] Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P Van Meerbeeck, Anna K Nowak, George Blumenschein Jr, Jonathan…
Read MoreComparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
JAMA Network Open 2022 March 1 [Link] Tomer Meirson, Francesca Pentimalli, Francesco Cerza, Giovanni Baglio, Steven G Gray, Pierpaolo Correale, Marija Krstic-Demonacos, Gal Markel, Antonio Giordano, David Bomze, Luciano Mutti Abstract Importance: Some recently proposed frontline therapies for malignant pleural mesothelioma (MPM) are very costly, yet their impact on quality of life and overall survival…
Read MoreNovel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review)
Molecular and Clinical Oncology 2022 April [Link] Erika Rijavec, Federica Biello, Giulia Barletta, Chiara Dellepiane, Carlo Genova Malignant pleural mesothelioma (MPM) is considered a relatively uncommon disease but its incidence is increasing worldwide. Patients affected by MPM have a very severe prognosis and have been often occupationally and environmentally exposed to asbestos. In recent years,…
Read MoreNovel and Future Treatment Options in Mesothelioma: A Systematic Review
International Journal of Molecular Sciences 2022 February 10 [Link] Danijela Štrbac, Vita Dolžan Abstract Mesothelioma is a rare tumor, frequently associated with asbestos exposure, arising from pleura and peritoneum. Traditionally, diagnosis and treatment have been difficult in a clinical setting. The treatment is based on a trimodal approach involving surgery, chemotherapy, and radiotherapy. The introduction…
Read MoreDynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
BMC Cancer 2022 February 20 [Link] Martina Vivoda Tomšič, Peter Korošec, Viljem Kovač, Sotirios Bisdas, Katarina Šurlan Popovič Abstract Background: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to…
Read MoreAbemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
The Lancet Oncology 2022 February 11 [Link] Dean A Fennell, Amy King, Seid Mohammed, Alastair Greystoke, Sarah Anthony, Charlotte Poile, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Anne Thomas, MiST2 study group Abstract Background: Genetically…
Read MoreCisplatin-Chelated Iminodiacetic Acid-Conjugated Hyaluronic Acid Nanogels for the Treatment of Malignant Pleural Mesothelioma in Mice
Molecular Pharmaceutics 2022 February 10 [Link] Yuki Amano, Kazuma L Sakura, Seiichi Ohta, Taichi Ito Abstract Malignant pleural mesothelioma (MPM) is one of the intractable cancers that require a more effective therapeutic strategy for clinical practice. Hyaluronic acid (HA) nanogels were prepared by the chelation of cisplatin (CDDP) with different molecular weights of iminodiacetic acid-conjugated…
Read More